European re evaluation of the benefit/risk balance of medicinal products containing finasteride or dutasteride

News Healthcare & Pharma Guidance

Date: 17th Oct, 2024 Source: French National Agency for the Safety of Medicines and Health Products (ANSM) Country: France Original Source

Brief

On "17/10/2024", the French National Agency for the Safety of Medicines and Health Products (ANSM) issued an update regarding European reevaluation of the benefit/risk balance of medicinal products containing finasteride or dutasteride. This follows a long-standing campaign to secure the use of medications containing 1mg finastéride, following the addition of suicidal thoughts as potential side effects.

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

European re evaluation of the benefit/risk balance of medicinal products containing finasteride or dutasteride

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

European re evaluation of the benefit/risk balance of medicinal products containing finasteride or dutasteride

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.